Skip to content
Mexico yesterday announced a modified decree regarding U.S. imports of biotech corn for animal feed. However, the change does not appear to stop the ban on […]
UPDATED: Mexico issues modified decree on biotech corn – but it’s not enough Read More »
Last week, Reuters reported that Doug McKalip, the new U.S. Trade Representative’s (USTR) Chief Agricultural Trade Negotiator, told Mexico that it has “until Feb.
Mexico needs to ‘explain the science’ behind its corn ban Read More »
Already, 2023 is looking like a dynamic year for biotech on the state level as state legislatures nationwide get ready to tackle a few
4 things for biotech to watch in the 2023 state legislatures Read More »
On Thursday, the Centers for Medicare & Medicaid Services (CMS) released its proposed timeline for penalizing drug makers whose prices rise faster than inflation.
CMS releases timeline for inflation rebate on drug price increases Read More »
The Biotechnology Innovation Organization (BIO) recently told the U.S. Patent and Trademark Office (USPTO) that proposed changes to the pharmaceutical patent process are flawed—and
BIO says that proposed changes to pharma patents would harm innovation Read More »
Partisan divisions were on display at a joint hearing of the House Energy & Commerce Committee’s Health and Oversight & Investigations subcommittees, as Republicans
Administration officials return to Congress to discuss COVID-19 response Read More »
Eleven years after the first CRISPR patent was filed, we’re anticipating what could be the first approval of a gene therapy based on CRISPR:
‘How do you price a cure?’ and other questions about the CRISPR era Read More »
In his State of the Union speech last night, President Joe Biden hailed the end of the COVID-19 emergency while ignoring the contribution of
State of the Union: Biden’s remarks on drug price controls and biomedical innovation Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
